Patents by Inventor Shigemitsu TAKEDA
Shigemitsu TAKEDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11267797Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 22, 2020Date of Patent: March 8, 2022Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Patent number: 11013728Abstract: The present invention aims to provide a novel cyclin-dependent kinase 8 and/or 19 inhibitor useful as an anti-cancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor containing a compound represented by the formula (I): [wherein each symbol is as defined in the DESCRIPTION] or a pharmaceutically acceptable salt thereof as an active ingredient, and use thereof as an agent for preventing and/or treating cancer.Type: GrantFiled: April 2, 2018Date of Patent: May 25, 2021Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Tatsuya Kitao, Shigemitsu Takeda, Yoshimichi Shoji, Hiroaki Shirahase
-
Publication number: 20210100783Abstract: The present invention aims to provide a novel cyclin-dependent kinase 8 and/or 19 inhibitor useful as an anti-cancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor containing a compound represented by the formula (I): [wherein each symbol is as defined in the DESCRIPTION] or a pharmaceutically acceptable salt thereof as an active ingredient, and use thereof as an agent for preventing and/or treating cancer.Type: ApplicationFiled: April 2, 2018Publication date: April 8, 2021Applicant: Kyoto Pharmaceutical Industries, Ltd.Inventors: Tatsuya KITAO, Shigemitsu TAKEDA, Yoshimichi SHOJI, Hiroaki SHIRAHASE
-
Publication number: 20200317630Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 22, 2020Publication date: October 8, 2020Applicants: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Patent number: 10689355Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 27, 2019Date of Patent: June 23, 2020Assignees: Kyoto Pharmaceuticals Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Publication number: 20190322636Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 27, 2019Publication date: October 24, 2019Applicants: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Patent number: 10377730Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 23, 2018Date of Patent: August 13, 2019Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Publication number: 20180265489Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 23, 2018Publication date: September 20, 2018Applicants: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Patent number: 10059663Abstract: Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.Type: GrantFiled: August 29, 2014Date of Patent: August 28, 2018Assignee: KYOTO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Hiroaki Shirahase, Kenji Takahashi, Yoshimichi Shoji, Shigemitsu Takeda
-
Patent number: 10005752Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 9, 2015Date of Patent: June 26, 2018Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Publication number: 20170121299Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 9, 2015Publication date: May 4, 2017Applicant: KYOTO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Publication number: 20160207883Abstract: Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.Type: ApplicationFiled: August 29, 2014Publication date: July 21, 2016Applicant: Kyoto Pharmaceutical Industries, Ltd.Inventors: Hiroaki SHIRAHASE, Kenji TAKAHASHI, Yoshimichi SHOJI, Shigemitsu TAKEDA